Evidence map›Paper›PMID 36014673›Full record

ArticleNanomaterials (Basel, Switzerland)2022

Ciprofloxacin-Loaded Silver Nanoparticles as Potent Nano-Antibiotics against Resistant Pathogenic Bacteria.

Duaa R Ibraheem, Nehia N Hussein, Ghassan M Sulaiman, Hamdoon A Mohammed, Riaz A Khan, Osamah Al Rugaie

Open access · goldAbstract read
In one paragraph

Article in Nanomaterials (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed
6.5field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 92 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Silver Nanoparticles fromMicroorganisms · 2025
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 3 countries.

Duaa R IbraheemDivision of Biotechnology, Department of Applied Sciences, University of Technology, Baghdad 10066, Iraq.ORCID 0000-0002-8262-708X
Nehia N HusseinDivision of Biotechnology, Department of Applied Sciences, University of Technology, Baghdad 10066, Iraq.
Ghassan M SulaimanDivision of Biotechnology, Department of Applied Sciences, University of Technology, Baghdad 10066, Iraq.ORCID 0000-0001-6388-3849
Hamdoon A MohammedDepartment of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, Qassim University, Buraidah 51452, Saudi Arabia.ORCID 0000-0003-2896-6790
Riaz A KhanDepartment of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, Qassim University, Buraidah 51452, Saudi Arabia.
Osamah Al RugaieDepartment of Basic Medical Sciences, College of Medicine and Medical Sciences, Qassim University, Unaizah 51911, Saudi Arabia.ORCID 0000-0001-8148-0138
Qassim University · SAUniversity of Technology - Iraq · IQ

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Silver nanoparticles (AgNPs) have demonstrated numerous physicochemical, biological, and functional properties suitable for biomedical applications, including antibacterial and drug carrier properties. In the present study, the antibiotic, ciprofloxacin (CIP), was loaded onto AgNPs, which were synthesized via the chemical reduction method, thereby enhancing CIP's antibacterial activity against Gram-negative (

Indexed as

antioxidantciprofloxacinnanocompositepathogenic bacteriaPEGsilver nanoparticles

Identifiers

PMID36014673
PMCPMC9415342
OpenAlexW4292258593

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.